Viewing Study NCT04446793

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:24 AM
Ignite Modification Date: 2026-05-10 @ 11:10 PM
Study NCT ID: NCT04446793
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2024-02-12
First Post: 2020-06-22
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
Sponsor: Cardiff Oncology
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Colorectal Cancer View
None KRAS Gene Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Colorectal Cancer View
None KRAS-Mutation View
None Onvansertib View
None PCM-075 View
None FOLFIRI View
None Irinotecan View
None 5-Fluoruracil View
None Bevacizumab View